Literature DB >> 24408158

HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma with genotypic infidelity and c-MYC expression.

Takao Kashiwagi1, Kentaro Minagawa, Hiroki Kawano, Tamaki Hirata, Sayaka Kashiwagi, Yoshihiro Nakagawa, Satoshi Kusaka, Takuma Suzuki, Tadahiro Inagaki, Minoru Kishi, Noriko Miwa, Sachiko Kimura, Miho Takechi, Makoto Koide, Masahide Iwai, Yoshio Katayama, Toshimitsu Matsui.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24408158     DOI： 10.1007/s00277-013-1999-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

Review 1.  Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.

Authors:  Savanah D Gisriel; Ji Yuan; Ryan C Braunberger; Danielle L V Maracaja; Xueyan Chen; Xiaojun Wu; Jenna McCracken; Mingyi Chen; Yi Xie; Laura E Brown; Peng Li; Yi Zhou; Tarsheen Sethi; Austin McHenry; Ronald G Hauser; Nathan Paulson; Haiming Tang; Eric D Hsi; Endi Wang; Qian-Yun Zhang; Ken H Young; Mina L Xu; Zenggang Pan
Journal:  Mod Pathol       Date:  2022-05-13       Impact factor: 8.209

2.  Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.

Authors:  Daisuke Kaji; Yasunori Ota; Yasuharu Sato; Koji Nagafuji; Yasunori Ueda; Masataka Okamoto; Yasushi Terasaki; Naoko Tsuyama; Kosei Matsue; Tomohiro Kinoshita; Go Yamamoto; Shuichi Taniguchi; Shigeru Chiba; Koichi Ohshima; Koji Izutsu
Journal:  Blood Adv       Date:  2020-09-22

3.  A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma.

Authors:  Daisuke Usuda; Masahisa Arahata; Kento Takeshima; Ryusho Sangen; Akiteru Takamura; Yasuhiro Kawai; Yuji Kasamaki; Yoshitsugu Iinuma; Tsugiyasu Kanda
Journal:  Case Rep Oncol       Date:  2017-11-16

4.  Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.

Authors:  Junghoon Shin; Jeong-Ok Lee; Ji-Young Choe; Soo-Mee Bang; Jong-Seok Lee
Journal:  Cancer Res Treat       Date:  2016-06-10       Impact factor: 4.679
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.